ABI H0731

Drug Profile

ABI H0731

Alternative Names: ABI-H0731

Latest Information Update: 31 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Indiana University
  • Developer Assembly Biosciences
  • Class Antivirals; Small molecules
  • Mechanism of Action Viral core protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 17 Apr 2017 Assembly Biosciences plans a phase I/II trial for Hepatitis B (Monotherapy, Combination therapy) in Australia, Hong Kong, South Korea, Taiwan and United Kingdom (NCT03109730)
  • 01 Nov 2016 Phase-I clinical trials in Hepatitis B (Combination therapy) in New Zealand (PO) (NCT02908191)
  • 01 Nov 2016 Phase-I clinical trials in Hepatitis B (Monotherapy) in New Zealand (PO) (NCT02908191)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top